News | News By Subject | News by Disease News By Date | Search News

Psoriatic Arthritis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Pfizer (PFE)'s Xeljanz Successful in Second Phase III Psoriatic Arthritis Study     6/7/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs     3/8/2016
Novartis AG (NVS) Wins Two New FDA Approvals for Cosentyx     1/19/2016
Amgen (AMGN) Dumps AstraZeneca PLC (AZN) Pact After Patients Developed Suicidal Thoughts     5/27/2015
Eli Lilly (LLY)'s Ixekizumab Succeeds in Late-Stage Study, Meets Primary Endpoint     4/22/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Analyst: Novartis AG (NVS), Celgene (CELG) Might Go Toe-to-Toe Over Psoriasis Drugs     9/26/2014
Celgene Corporation (CELG) Wins FDA Approval For Pill To Treat Psoriatic Arthritis     3/25/2014
Celgene Corporation (CELG) Arthritis Drug Appears Effective, Safe After One Year: Study     10/28/2013
Health Canada Approves Centocor Ortho Biotech Inc. and Schering-Plough Corporation (SGP)'s SIMPONI(TM) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis; First World Regulatory Approval for SIMPONI     4/14/2009
Centocor, Inc. (JNJ) Submits Application to FDA (JOBS) Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis     6/27/2008
FDA Expands Centocor, Inc. (JNJ)'s REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown To Inhibit Joint Damage And Improve Physical Function     8/14/2006
Biogen Idec, Inc. (Massachusetts) (BIIB) Promising AMEVIVE(R) Phase II Psoriatic Arthritis Data Presented At American College of Rheumatology Meeting     11/15/2005
Abbott Laboratories' (ABT) Humira Gets Additional OK For Psoriatic Arthritis     10/4/2005

News from Around the Web

Press Releases
MorphoSys AG Announces That Its Licensee Janssen Biotech (JNJ) Has Initiated Two Phase III Studies With Tremfyatm (Guselkumab) In Psoriatic Arthritis     9/21/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (ixekizumab) Demonstrated No Progression Or Minimal Progression Of Radiographic Disease In Patients With Psoriatic Arthritis Through 52 Weeks     6/16/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (Ixekizumab) Demonstrated Significant Improvements In Disease Signs And Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors     6/15/2017
Janssen Pharmaceutical Release: New Phase III Data Show Anti-TNF Alpha SIMPONI ARIA (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis     6/14/2017
Pfizer (PFE) Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For XELJANZ (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis     5/3/2017
Galapagos (GLPG.BR) Doses First Psoriatic Arthritis Patient With Filgotinib     4/6/2017
Janssen Biotech (JNJ) Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis     12/21/2016
Janssen R&D Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial     11/15/2016
Pfizer (PFE) Announces Results From Phase III OPAL Clinical Development Program Investigating XELJANZ (Tofacitinib Citrate) For Psoriatic Arthritis     11/15/2016
Celgene (CELG) Release: Data On Early Onset Of Efficacy For Oral Otezla (Apremilast) In Active Psoriatic Arthritis Presented At American College of Rheumatology     11/14/2016
Pfizer (PFE) To Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis And Psoriatic Arthritis     11/7/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101)     6/7/2016
AbbVie (ABBV)'s Leadership In Gastroenterology Showcased At Digestive Disease Week With New HUMIRA (Adalimumab) Long-Term, Real-World Research And Promising Anti-IL-23 Antibody Late-Breaking Data     5/19/2016
New Novartis AG (NVS) Data Show Cosentyx Demonstrated Sustained Superiority In Skin Clearance (PASI 90) Versus Stelara At Week 52     3/7/2016
Approximately 80% Of Psoriatic Arthritis Patients Treated With Cosentyx Saw No Progression Of Joint Damage As Shown In Novartis Pharmaceuticals Corporation (NVS) New Two-Year Observational Data     11/9/2015